Status:
COMPLETED
Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Conditions:
Rectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine if positron emission tomography (PET) imaging with an imaging agent called 18F-fluorodeoxythymidine(\[18F\]-FLT) will allow investigators to measure how well ...
Eligibility Criteria
Inclusion
- Subjects with known rectal cancer.
- Subjects must have signed an approved consent form.
- Subjects must be 18 years of age or older.
Exclusion
- Children less than 18 are excluded.
- Pregnant women and women who are breast feeding will be excluded from this study. A serum beta HCG will also be performed for each pre-menopausal female subject.
- Patients who are acutely ill who are deemed by their treating physician as not suitable candidates for this study
Key Trial Info
Start Date :
March 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01207895
Start Date
March 1 2010
End Date
July 1 2013
Last Update
February 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232